Maxwell Skor
Stock Analyst at Morgan Stanley
(4.75)
# 639
Out of 4,712 analysts
239
Total ratings
70.1%
Success rate
24.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintained: Buy | $273 | $270.09 | +1.08% | 29 | Sep 8, 2026 | |
| PHVS Pharvaris | Maintained: Buy | $46 | $37.84 | +21.56% | 91 | Sep 8, 2026 | |
| RARE Ultragenyx Pharmaceutical | Downgraded: Hold | $74 → $18 | $14.88 | +20.97% | 14 | Sep 3, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $60 | $54.78 | +9.53% | 3 | Aug 28, 2026 | |
| INSM Insmed | Maintained: Buy | $218 | $124.89 | +74.55% | 27 | Aug 24, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Hold | n/a | $4.18 | - | 9 | Aug 17, 2026 | |
| MNPR Monopar Therapeutics | Rated: Buy | $115 → $130 | $114.38 | +13.66% | 4 | Aug 17, 2026 | |
| SANA Sana Biotechnology | Rated: Buy | $12 | $3.45 | +247.83% | 4 | Aug 17, 2026 | |
| ADAG Adagene | Maintained: Hold | n/a | $3.49 | - | 7 | Aug 17, 2026 | |
| TCRX TScan Therapeutics | Maintained: Hold | n/a | $0.3448 | - | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $7.84 | +65.82% | 1 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $7 | $5.68 | +23.24% | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $103 | $75.35 | +36.70% | 21 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9.5 → $3.55 | $0.8258 | n/a | 10 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.25 | $0.7401 | n/a | 1 | Sep 25, 2023 |
Ascendis Pharma
Sep 8, 2026
Maintained: Buy
Price Target: $273
Current: $270.09
Upside: +1.08%
Pharvaris
Sep 8, 2026
Maintained: Buy
Price Target: $46
Current: $37.84
Upside: +21.56%
Ultragenyx Pharmaceutical
Sep 3, 2026
Downgraded: Hold
Price Target: $74 → $18
Current: $14.88
Upside: +20.97%
CRISPR Therapeutics AG
Aug 28, 2026
Maintained: Hold
Price Target: $60
Current: $54.78
Upside: +9.53%
Insmed
Aug 24, 2026
Maintained: Buy
Price Target: $218
Current: $124.89
Upside: +74.55%
Bicycle Therapeutics
Aug 17, 2026
Maintained: Hold
Price Target: n/a
Current: $4.18
Upside: -
Monopar Therapeutics
Aug 17, 2026
Rated: Buy
Price Target: $115 → $130
Current: $114.38
Upside: +13.66%
Sana Biotechnology
Aug 17, 2026
Rated: Buy
Price Target: $12
Current: $3.45
Upside: +247.83%
Adagene
Aug 17, 2026
Maintained: Hold
Price Target: n/a
Current: $3.49
Upside: -
TScan Therapeutics
Aug 17, 2026
Maintained: Hold
Price Target: n/a
Current: $0.3448
Upside: -
Aug 13, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $7.84
Upside: +65.82%
Aug 13, 2026
Rated: Hold
Price Target: $6 → $7
Current: $5.68
Upside: +23.24%
Jul 23, 2026
Rated: Buy
Price Target: $103
Current: $75.35
Upside: +36.70%
Nov 20, 2024
Maintained: Buy
Price Target: $9.5 → $3.55
Current: $0.8258
Upside: n/a
Sep 25, 2023
Downgraded: Hold
Price Target: $3.25
Current: $0.7401
Upside: n/a